Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Wake Forest Baptist Health Identifier:
First received: February 2, 2001
Last updated: August 20, 2009
Last verified: August 2009

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gemcitabine may make tumor cells more sensitive to radiation therapy. Combining chemotherapy with radiation therapy after surgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with radiation therapy in treating patients who have undergone surgery to remove cancer of the pancreas.

Condition Intervention Phase
Pancreatic Cancer
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Trial Of Adjuvant 2'2'-Difluoro-2'-Deoxycytidine (Gemcitabine) And External Beam Radiation For The Treatment Of Resectable Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Wake Forest Baptist Health:

Study Start Date: December 2000
Detailed Description:


  • Determine the time to disease progression, local control, and survival of patients with previously resected pancreatic cancer treated with adjuvant gemcitabine and radiotherapy.

OUTLINE: This is a multicenter study.

Patients receive gemcitabine IV over 30-60 minutes on days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32 and undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38 in the absence of disease progression or unacceptable toxicity.

Beginning at least 4 weeks after chemoradiotherapy, patients without disease progression and with less than 10% weight loss during study receive additional gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 2 courses.

Patients are followed every 8 weeks for 6 months and then every 3 months for up to 2 years.

PROJECTED ACCRUAL: A total of 72 patients will be accrued for this study within 2.2 or 3.4 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed invasive adenocarcinoma of the pancreas

    • Prior gross total resection via a pancreaticoduodenectomy (Whipple resection or total pancreatectomy) within the past 2 months
  • No clinical evidence of gross residual disease at time of surgery

    • No focally positive margins (tumor at the margin)
  • No unresected nodal disease or metastatic disease to the liver, peritoneal surfaces, or elsewhere



  • Over 18

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 6 months


  • Granulocyte count greater than 1,500/mm3
  • Hemoglobin greater than 10 g/dL
  • Platelet count greater than 100,000/mm3


  • Bilirubin less than 2.0 mg/dL


  • Creatinine less than 2.0 mg/dL


  • Able to maintain adequate oral nutrition
  • Documented stable weight (no more than 5 lbs weight loss) for at least 2 weeks prior to study
  • No other malignancy within the past 2 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix or breast
  • Non-metastatic prostate cancer allowed if more than 2 year survival likely
  • No other serious medical or psychiatric illness that would preclude study or limit survival to less than 2 years
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • No concurrent routine growth factors


  • No prior chemotherapy for pancreatic cancer

Endocrine therapy:

  • Not specified


  • No prior abdominal radiotherapy for pancreatic cancer


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00010166

United States, North Carolina
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States, 27157-1082
Sponsors and Collaborators
Wake Forest Baptist Health
National Cancer Institute (NCI)
Study Chair: Arthur William Blackstock, MD Comprehensive Cancer Center of Wake Forest University
  More Information

Additional Information:
Publications: Identifier: NCT00010166     History of Changes
Other Study ID Numbers: CDR0000068452, CCCWFU-57198, NCI-104
Study First Received: February 2, 2001
Last Updated: August 20, 2009
Health Authority: United States: Federal Government

Keywords provided by Wake Forest Baptist Health:
stage I pancreatic cancer
adenocarcinoma of the pancreas

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on October 13, 2015